Helping people with communication difficulties after stroke to understand warfarin therapy
|
|
|
- Lynette McLaughlin
- 5 years ago
- Views:
Transcription
1 Helping people with communication difficulties after stroke to understand warfarin therapy Satinder Bhandal, Consultant Anticoagulation Pharmacist, Buckinghamshire Healthcare Trust and UK Clinical Pharmacy Association Nina Barnett Consultant pharmacist, Older People, Medicines Use and Safety Division, NHS Specialist Pharmacy Service Katrina Clarkson Principal Speech and Language Therapist, London North West Healthcare NHS Trust
2 What is aphasia? Loss or impairment of language function caused by brain damage Aphasia is a multimodal disorder: Difficulties in speaking, understanding, reading, writing Reduction in capacity to interpret and formulate linguistic elements (e.g. sentences, words, morphemes the smallest grammatical unit in a language) Murdoch (2010)
3 Who experiences aphasia? People who have had a stroke Brain tumour (primary or secondary) Traumatic head injury Hypoxic brain injury
4 Who needs anticoagulation Stroke - AF Other reasons Deep Vein Thrombosis Pulmonary Embolus Mechanical heart value Pulmonary hypertension Severe cardiomyopathy
5 Atrial Fibrillation some facts Prevalence - 1.7% in England in 2012/13 Incidence of stroke attributable to AF is 1.5% in those aged 50 to 59 years It rises to 23.5% for between 80 and 89 years Counselling elderly patients many with multiple co-morbidities, polypharmacy and reduced cognition challenging In addition some of those will already have suffered a stroke which may result in preexisting aphasia
6 Which anticoagulant? Warfarin Advantages of warfarin Tried and tested well tolerated easy to monitor adherence keeps you connected with health system More experience in reversing and antidote available Disadvantages of warfarin Complex dosing regimen Slow onset Frequent monitoring trips Drugs and food interaction
7 What about DOACs (direct oral anticoagulants)? Advantages of DOACs Simple dosing regimens fast acting (vs warfarin can take ages to get to an effective level) less drug and food interaction less treatment burden (convenience) Some DOACs can be put in compliance aids Disavantages DOAC less well tolerated (eg one in five people stop after 2 year, rash, headache, fuzziness, GI side effect (diarrhoea can be disabling) Other than dabigatran, no licenced antidote
8 NPSA 2006 Anticoagulant risk assessment Several participants with strokes stressed the need for doctors to give appropriate time to patients with aphasia to ensure that they properly understood their medication. You WILL need extra time to counsel the patient with aphasia So, a new tool may help...
9 What do we use now? Anticoagulation therapy Pack ( yellow book ) Patient information booklet Alert card for patient Record of INR book Treatment sheets
10 What do we need to communicate effectively to patient with aphasia? Short message Clear sentences Easy words Good layout Diagrams and pictures Appropriate font
11 What did we create Learning event with pharmacist and speech and language therapist Agreed on simple, accessible, online tool which can be downloaded for local use Powerpoint slides using SLT guidance for presentation and pharmacist guidance for content For example..
12 Yellow book - warfarin doses
13 Your new tablet is Warfarin The tablets are 1mg 3mg 5mg different strengths Bucks Healthcare & NHS Specialist Pharmacy Service 2015
14 Take Warfarin once a day When will you remember to take it? Bucks Healthcare & NHS Specialist Pharmacy Service 2015
15 Yellow book - INR
16 You will need regular blood tests The test is INR It shows how much warfarin you need If you are ill you need an extra blood test that week Bucks Healthcare & NHS Specialist Pharmacy Service 2015
17 Yellow book dietary interactions
18 Foods All foods are okay Keep what you eat the same each week Bucks Healthcare & NHS Specialist Pharmacy Service 2015
19 Yellow book - alcohol
20 Do not drink lots of alcohol Keep what you drink the same each week Bucks Healthcare & NHS Specialist Pharmacy Service 2015
21 Summary for healthcare professionals Blood tests (INR) Take Warfarin every day No big changes to diet No binge alcohol If very ill get extra blood test that week Tell family and health professionals you are on Warfarin Bucks Healthcare & NHS Specialist Pharmacy Service 2015
22 Where can you get a copy? Tool freely available to download Now includes DOACs Bucks Healthcare & NHS Specialist Pharmacy Service 2015
23 Acknowledgements Satinder Bhandal, Consultant pharmacist Anticoagulation, Buckinghamshire Healthcare NHS. Trust Frances Akor, Consultant Pharmacist Anticoagulation, Imperial College Healthcare NHS Trust. Katrina Clarkson, Principal Speech and Language Therapist, Regional Hyperacute Rehabilitation Unit, Northwick Park Hospital, Clare Cahoon, Highly Specialist Speech and Language Therapist, Regional Hyperacute Rehabilitation Unit, Northwick Park Hospital, Nina Barnett Consultant Pharmacist, Older People, Medicines Use and Safety Division, NHS Specialist Pharmacy Service and London North West Healthcare NHS Trust With thanks to the UKCPA HAT group, Estelle Bloom at Making It Clear and the patients of Bucks Healthcare Trust. Bucks Healthcare and Medicines Use and Safety Division, NHS Specialist Pharmacy Service 2015
Warfarin Atrial Fibrillation Consultations A Visual Support Tool
Warfarin Atrial Fibrillation Consultations A Visual Support Tool Bucks Healthcare and Medicines Use and Safety Division, NHS Specialist Pharmacy Service 2017 1 Your new tablet is Warfarin 1mg 3mg 5mg The
Atrial Fibrillation and Anticoagulants
Atrial Fibrillation and Anticoagulants A guide to your diagnosis and treatment Information for patients, relatives and carers For more information, please contact: York Anticoagulant Clinic Tel: 01904
Appendix 8 Patient Information Leaflet A. NPSA Web Link www.npsa.nhs.uk/easysiteweb/gatewaylink.aspx?alid=19112 B. Supplementary NT 1. WHY AM I ON WARFARIN? Your doctors have told you that you have a condition
Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting
ANTICOAGULANT SERVICE Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting Introduction Fast loading of warfarin carries a risk of over anticoagulation
Pulmonary Embolism (PE)
Pulmonary Embolism (PE) Normally blood moves freely throughout the body without any problems. However, if a blood clot forms in a vein it can block the vein and stop the blood from flowing properly. Sometimes
Tackling atrial fibrillation the health economics evidence
Tackling atrial fibrillation the health economics evidence Professor Gary Ford,CBE Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford University Hospitals
Thrombosis and Anticoagulation Team. Warfarin. Information for patients, relatives and carers
Thrombosis and Anticoagulation Team Warfarin Information for patients, relatives and carers What is warfarin? Warfarin is an anticoagulant. Anticoagulants are drugs which prevent harmful blood clots forming
pat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
Novel oral anticoagulant therapy (NOAC)
Haematology Department Novel oral anticoagulant therapy (NOAC) Information for patients, relatives and carers What is novel oral anticoagulant therapy? Novel oral anticoagulants, or NOACs, are drugs which
Atrial fibrillation and anticoagulation therapy
Atrial fibrillation and anticoagulation therapy This leaflet offers more information about atrial fibrillation for patients who have been advised that they need anticoagulation therapy. If you have any
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
A review of aphasia. Katrina Clarkson Principal Speech and Language Therapist, Regional Rehabilitation Unit, Northwick Park Hospital
A review of aphasia Katrina Clarkson Principal Speech and Language Therapist, Regional Rehabilitation Unit, Northwick Park Hospital 07.10.14 Defining Aphasia Loss or impairment of language function caused
References: Murtagh J. Murtagh s General Practice. 5 th edn. Sydney: McGraw Hill; 2010.
This presentation is designed to be delivered to people who work in a health care setting; such as nurses, carers and other nursing home staff. If you are an accredited pharmacist, you can use this presentation
The first stop for professional medicines advice. Community Pharmacy Oral Anticoagulant Safety Audit
Community Pharmacy Oral Anticoagulant Safety Audit This audit has been developed with help and support from the following organisations: Community Pharmacy Patient Safety Group PharmOutcomes Pharmaceutical
AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
Cerebral Venous Thrombosis (CVT)
Cerebral Venous Thrombosis (CVT) Humphrey Booth Building Neurosciences 0161 206 4221 All Rights Reserved 2017. Document for issue as handout. Unique Identifier: NOE34(17). Review date: July 2019 What is
Patient Sticky Label. A Resource Guide for Stroke Survivors and their Caregivers
A Resource Guide for Stroke Survivors and their Caregivers Patient Sticky Label An initiative of the Stroke Services Improvement (SSI) team in collaboration with all public hospitals in Singapore. Learning
Warfarin. Information for patients taking warfarin
Warfarin Information for patients taking warfarin Read this booklet to learn: what warfarin is and why you are taking it what blood tests you need to use warfarin safely how other medicines and diet can
Living with a New Oral Anticoagulant (NOAC)
Living with a New Oral Anticoagulant (NOAC) dabigatran (Pradaxa ) rivaroxaban (Xarelto ) apixaban (Eliquis ) Information for patients Produced and made available by the Western Australian Medication Safety
Location of initiative York Region Chronic Kidney Disease Program, Mackenzie Richmond Hill Hospital, Richmond Hill, ON
Story #1 CSHP 2015 objective Objective 2.1 - In 70% of ambulatory and specialized care clinics providing clinic care, pharmacists will manage medication therapy for clinic patients with complex and high-risk
What is aphasia? Katrina Clarkson Principal Speech and Language Therapist, Regional Rehabilitation Unit, Northwick Park Hospital
What is aphasia? Katrina Clarkson Principal Speech and Language Therapist, Regional Rehabilitation Unit, Northwick Park Hospital 11.02.14 Defining Aphasia Loss or impairment of language function caused
Direct Oral Anticoagulant (DOAC)Therapy. Important information for patients prescribed: Apixaban, Dabigatran, Edoxaban or Rivaroxaban
Direct Oral Anticoagulant (DOAC)Therapy Important information for patients prescribed: Apixaban, Dabigatran, Edoxaban or Rivaroxaban Patient Name: Address: Postcode: CHI Number: Condition requiring treatment:
Anticoagulation in Atrial Fibrillation Patient information
Anticoagulation in Atrial Fibrillation Patient information Introduction This leaflet will help you understand your new medicine. Your new medicine is commonly known as a blood thinner because that is what
Atrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
Adherence to VKA treatments : What are the needs?
Adherence to VKA treatments : What are the needs? Marie-Camille Chaumais Antoine Béclère Hospital Clamart, France 1 No conflict of interest 2 1 According to NICE, between a third and a half of all medicines
CARDIAC REHABILITATION PROGRAMME:- MEDICATION
CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to
Surgery for Patients on Oral Anticoagulants
Surgery for Patients on Oral Anticoagulants (for example: warfarin, rivaroxaban, apixaban, dabigatran, edoxaban) Surgery Patient Information Leaflet You have been given this leaflet because you are due
Warfarin PATIENT EDUCATION
Warfarin PATIENT EDUCATION Information for patients taking warfarin Read this booklet to learn: What warfarin is and why you are taking it What blood tests you need to use warfarin safely How other medicines
DOAC support programme. engage supported self-care
DOAC support programme engage supported self-care changes in anticoagulation therapy Managing patients receiving anticoagulation (AC) therapy effectively and consistently can be challenging. Direct oral
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
Are There Any Special Instructions When Taking Warfarin
Are There Any Special Instructions When Taking Warfarin Prescriptions drugs of concern when taking warfarin include: Follow the instructions of your health care provider and read carefully all product
Treatment with Rivaroxaban Xarelto
Treatment with Rivaroxaban Xarelto Anticoagulation Clinic This handout explains the medicine rivaroxaban, a drug that helps prevent blood clots. What is rivaroxaban? Rivaroxaban (brand name Xarelto) is
Anticoagulant treatment for DVT
Anticoagulant treatment for DVT A guide to your diagnosis and the choice of treatment For more information, please contact: Please see contact details on page 23 of this booklet Caring with pride 2 Caring
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Thank you for agreeing to give us a statement on your organisation s view of the technology and the way
Rivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
Things to Know When Taking Warfarin (Coumadin ) Anticoagulation Therapy
Things to Know When Taking Warfarin (Coumadin ) Anticoagulation Therapy Table of Contents Highlights... 1 Why Do I Need Warfarin (Coumadin )?... 1 Who is Going to be Taking Care of My Warfarin?... 1 What
Atrial fibrillation. Understanding NICE guidance
Understanding NICE guidance Information for people who use NHS services Atrial fibrillation NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases and the treatments
Helping to prevent stroke caused by non-valvular atrial fibrillation Information booklet
Helping to prevent stroke caused by non-valvular atrial fibrillation Information booklet IF FOUND, PLEASE RETURN TO: Name Address Phone number Contents ALERT CARD...2 BOOKLET INFORMATION...3 What is atrial
DRUG NAME: EDOXABAN (LIXIANA ) Transfer of Care document Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral
Pradaxa. [dabigatran etexilate] patient support booklet
![Pradaxa. [dabigatran etexilate] patient support booklet](/thumbs/78/77038668.jpg "Pradaxa. [dabigatran etexilate] patient support booklet")
Pradaxa [dabigatran etexilate] patient support booklet Important information about your medication and how to take it to help you reduce your risk of stroke associated with atrial fibrillation You have
Imaging Department Investigative procedure information leaflet Percutaneous biopsy of Lung (CT guided)
Imaging Department Investigative procedure information leaflet Name of procedure: Percutaneous biopsy of Lung (CT guided) It has been recommended you have a biopsy of your lung using CT (computerised tomography,
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
Atrial fibrillation patient decision aid: Antithrombotic therapy
Atrial fibrillation patient decision aid: Antithrombotic therapy What this decision aid is for This decision aid is intended to assist health professionals in consultations with patients with atrial fibrillation
Adjusting the way to speak when communicating with people who have visual impairment and additional needs
Adjusting the way to speak when communicating with people who have visual impairment and additional needs Ian Bell Specialist Independent Speech and Language Therapist Article 17 in the series Facilitating
Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
Clinical Guide - Patient Information (January 2007)
Clinical Guide - Patient Information (January 2007) Principal Developer: B. Bartle Secondary Developers: J. Johnson, M-F. Scully, L. Vickars Information For Patients Taking Oral Anticoagulants You are
To prevent blood clots after hip or knee replacement surgery This booklet contains information for those who have been prescribed ELIQUIS (apixaban)
To prevent blood clots after hip or knee replacement surgery This booklet contains information for those who have been prescribed ELIQUIS (apixaban) after hip or knee replacement surgery Always read the
CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES
National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) MMCP05 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist
The Neuro-rehabilitation enhanced transition team (NETT)
The Neuro-rehabilitation enhanced transition team (NETT) A community neurological rehabilitation service for Lambeth and Southwark Who we are We are a community team that aims to support you and your family
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES
National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) CP11 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION The
NOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions
AC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions FAQ document jointly prepared by NHSGGC Haematology Service & Medicines Infmation On behalf of the Heart MCN
Direct Current Cardioversion (DCCV)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a This is a procedure carried out under a brief anaesthetic, which uses a
Treatment with Apixaban Eliquis
Treatment with Apixaban Eliquis Anticoagulation Clinic 416-530-6000 ext 3477 This handout explains the medicine rivaroxaban, a drug that helps prevent blood clots. What is apixaban? Apixaban (brand name
INTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
Improving medication safety
Improving medication safety Information for patients and carers To improve medicines safety it is crucial to be able to identify medicines related patient safety incidents such as medicines incidents,
Local steroid injections to joints and soft tissues
Local steroid injections to joints and soft tissues Pain Management Team Patient Information Leaflet Introduction This leaflet will provide you with information about what to expect when you come in for
WARFARIN ANTICOAGULANT RECORD
WARFARIN ANTICOAGULANT RECORD Provided as a service to medicine by Concordia International Rx UK Ltd HOSPITAL/GP PRACTICE:... Telephone:... ANTICOAGULANT CLINIC Telephone:... Name:... Address:...... Telephone:...
bpac better e m dicine
INR Testing Quiz Feedback bpac nz better medicin e Contents INR Testing Quiz 2 Quiz Feedback: Responses from Colleagues, and Expert Review 4 bpac nz Review : Dr Janine Bailey, Motueka Dr Stephen Kuzmich,
Cervical cancer screening event summary
Cervical cancer screening event summary The North East and Cumbria learning disability network held a cervical cancer screening event on 9 th December at The Dolphin Centre in Darlington. This booklet
GRASP-AF- The National Picture. Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012
GRASP-AF- The National Picture Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012 Outline AF and stroke Objective Management of stroke risk Stroke risk
Use of unlicensed medicines and off-label uses
Use of unlicensed medicines and off-label uses 25 Promoting hope and wellbeing together What is this leaflet about? Your doctor or pharmacist has given you this leaflet because a medicine that you have
Community Pharmacy Safety in Practice Warfarin Change Package 2017
Community Pharmacy Safety in Practice Warfarin Change Package 2017 1 Community Pharmacy Safety in Practice Community Pharmacy Safety in Practice 2017/2018 is a pilot programme. We want to make it suit
AF A. The reality of life on Anticoagulation therapy. A report by the Atrial Fibrillation Association and AntiCoagulation Europe
Date of preparation: February 2012 UK/DBG - 111081 The reality of life on Anticoagulation therapy A report by the Atrial Fibrillation Association and AntiCoagulation Europe The report was prepared with
NHS Lanarkshire Care Homes Protocol Group. Warfarin Guidance and Administration Record for Care Homes
NHS Lanarkshire Care Homes Protocol Group Warfarin Guidance and Administration Record for Care Homes Author: Endorsing Body: Governance or Assurance Committee Implementation Date: July 2017 Version Number:
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE HELEN WILLIAMS FFRPS, MRPHARMS, PGDIP (CARDIOL) IPRESC CONSULTANT PHARMACIST FOR CVD, SOUTH LONDON CLINICAL LEAD FOR ATRIAL FIBRILLATION, HEALTH INNOVATION
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Rivaroxaban is a non-vitamin K antagonist oral anticoagulant
Show Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
Policy for the safe use of oral methotrexate
Policy for the safe use of oral methotrexate Policy Checklist Name of Policy: Purpose of Policy: Directorate responsible for Policy Name & Title of Author: Does this meet criteria of a Policy? Staff side
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC)
Tacrolimus. Information for patients about using the drug Tacrolimus.
Tacrolimus Information for patients about using the drug Tacrolimus. Your consultant has recommended you start treatment with tacrolimus. This leaflet has been developed to provide you with additional
Robotic-assisted lingual tonsillectomy for sleep apnoea
Robotic-assisted lingual tonsillectomy for sleep apnoea You have been given this leaflet because you have been referred for a robotic-assisted lingual tonsillectomy for sleep apnoea. This leaflet offers
UW MEDICINE PATIENT EDUCATION. Treating Blood Clots. What is a blood clot? DRAFT
UW MEDICINE PATIENT EDUCATION Treating Blood Clots About deep vein thrombosis (DVT) and pulmonary embolism (PE) and how they are treated This handout explains blood clots, their symptoms, and how they
Apixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
18/09/2012. Dr. Khalid Khan Consultant Cardiologist BCUHB. Oral Anticoagulation Update Day 12 th September 2012 University of Birmingham
Dr. Khalid Khan Consultant Cardiologist BCUHB Oral Anticoagulation Update Day 12 th September 2012 University of Birmingham 1 NICE vs. Local Guidance NICE says no We say no NICE says yes We say no NOACs
Edoxaban Switch Programme - Frequently Asked Questions
Edoxaban Switch Programme - Frequently Asked Questions What should I tell patients? NHS Tayside is reviewing all patients currently receiving a Direct Oral Anticoagulant (DOAC) for stroke prevention in
Methotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
Medicines for stroke prevention in atrial fibrillation. Choosing the right one for you
Medicines for stroke prevention in atrial fibrillation Choosing the right one for you Atrial fibrillation (AF) is a condition that affects the heart, causing it to beat irregularly and too fast. When this
Treatment of deep vein thrombosis and pulmonary embolism with low molecular weight heparin
Treatment of deep vein thrombosis and pulmonary embolism with low molecular weight heparin You have been given this leaflet because you have a blood clot. Normally blood flows freely around the body without
Aim. Managing high risk medicines in primary care. Intended outcomes. Introduction. Risk associated with prescribing
Aim Managing high risk medicines in primary care To increase awareness of high risk medicines and combinations of medicines and to ensure the appropriate prescribing, supply or administration of such in
This booklet has been provided to help answer some of the questions you may have about RFA of liver tumours.
This booklet has been provided to help answer some of the questions you may have about RFA of liver tumours. RFA of tumours is a minimally invasive procedure used to treat liver tumours (growth or mass
easy read Your rights under THE accessible InformatioN STandard
easy read Your rights under THE accessible InformatioN STandard Your Rights Under The Accessible Information Standard 2 1 Introduction In July 2015, NHS England published the Accessible Information Standard
Amiodarone Therapy. Exceptional healthcare, personally delivered
Amiodarone Therapy Exceptional healthcare, personally delivered Your information Name: Address: Postcode: Home telephone: Mobile telephone: Hospital number: Name of GP: Address: Postcode: Telephone number:
2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
NHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation
1 NHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation Atrial fibrillation (AF) affects about 1.2% of the population in the United Kingdom and accounts
Blood-thinning medication after stroke
Call the Stroke Helpline: 0303 3033 100 or email: info@stroke.org.uk Blood-thinning medication after stroke Blood-thinning medicines are drugs that help to prevent clots forming in your blood. They are
Steps Against Recurrent Stroke (STARS)
Steps Against Recurrent Stroke (STARS) Take steps against recurrent stroke by making the necessary changes in your life. Your Guide to Ischemic Stroke What happened to me? You had a stroke. The stroke
Managing low-risk basal cell carcinomas in the community
Understanding NICE guidance Information for people who use NHS services Managing low-risk basal cell carcinomas in the community NICE guidance on cancer services recommends how healthcare services for
Physical Activity and Heart Failure:
Queensland Health Physical Activity and Heart Failure: Helping your heart by being active Artwork Story This artwork represents Aboriginal and Torres Strait Islander cultures in Queensland. It speaks of
Patient Information. Acute Kidney Injury (AKI)
Patient Information Acute Kidney Injury (AKI) My doctor said I have AKI - what is AKI? AKI is short for acute kidney injury. Some people used to call it acute renal failure. If you have AKI, it means your
PULL OUT AND KEEP THIS CPD MODULE PLUS PRE-TEST AND POST-TEST IS ONLINE AT PHARMACYMAGAZINE.CO.UK PHARMACY MAGAZINE
This module is also online at 8 CPD MODULE module 243 Welcome to the two hundred and forty third module in the Pharmacy Magazine Continuing Professional Development Programme, which looks at medicines
Oral N-Acetyl CystieneTablets. Patient Information
Oral N-Acetyl CystieneTablets Patient Information Author ID: AA Leaflet Number: Resp 001 Version: 4 Name of Leaflet: Oral N-Acetyl Cystiene Tablets Date Produced: August 2017 Review Date: August 2019 N-acetyl
Rivaroxaban. medication do? Xarelto. is a blood. Medication. Emboli (PE).
Medication Information (Ri va rox xa - ban) Other names for this medication: Xarelto What does this medication do? This medication is a blood thinner, also called an anticoagulant. It prevents a blood
Treating atrial fibrillation using heat energy delivered to the outside of the heart through a thin tube
Issue date March 2009 Understanding NICE guidance Information for people who use NHS services NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical
Breast Cancer and Breast Screening
Breast Cancer and Breast Screening Breast Cancer Breast Cancer is the most common cancer in this country. Women and Men can get Breast Cancer. More women than men get Breast Cancer. 1 in 8 women get Breast
Olanzapine Long Acting Injection (LAI) Guideline
Olanzapine Long Acting Injection (LAI) Guideline Guidance and Procedure for the use of Olanzapine Hertfordshire Partnership University NHS Foundation Trust Version: 1.0 Lead Author: Chief Pharmacist Approved
Anticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration